Transcatheter treatment of Starr-Edwards paravalvular leaks.

J Cardiovasc Med (Hagerstown)

Paediatric Cardiology, A.O.R.N. 'Ospedali dei Colli', 2nd University of Naples, Naples, Italy.

Published: December 2016

: A 56-year-old patient was referred because of refractory heart failure and mild haemolysis caused by multiple, severe paravalvular leaks of a Starr-Edwards valve implanted in mitral position 23 years before. Owing to perceived high risk of surgical re-valving, percutaneous paravalvular leak occlusion was performed by implantation of multiple, simultaneously deployed Amplatzer Vascular Plugs.

Download full-text PDF

Source
http://dx.doi.org/10.2459/JCM.0000000000000105DOI Listing

Publication Analysis

Top Keywords

paravalvular leaks
8
transcatheter treatment
4
treatment starr-edwards
4
starr-edwards paravalvular
4
leaks 56-year-old
4
56-year-old patient
4
patient referred
4
referred refractory
4
refractory heart
4
heart failure
4

Similar Publications

Background: There are several high-risk treatment options for valve failure of a biological full root replacement. When tailoring the best treatment option for the patient, implantation of a rapid deployment valve (RDV) should be considered.

Case Presentation: Six patients presented with aortic regurgitation in a full root Freestyle bioprosthesis.

View Article and Find Full Text PDF

Background: Vascular complications remain prevalent on transfemoral transcatheter aortic valve replacement (TF-TAVR) with a significant proportion related to the secondary arterial access. We hypothesized that placing the second sheath ipsilateral and distal to the delivery sheath could reduce vascular complications with similar safety and efficacy.

Objectives: Comparing vascular complications and clinical outcomes when placing the secondary arterial sheath in the ipsilateral (unilateral-access) versus in the contralateral (bilateral-access) femoral artery during TF-TAVR.

View Article and Find Full Text PDF

Background: The Hydra CE study revealed 1-year favorable efficacy of TAVR, showing a large effective orifice area (EOA), low gradient, and acceptable complication rates.

Aims: We evaluated the 3-year clinical and hemodynamic outcomes of Hydra self-expanding transcatheter aortic valve (manufactured by Vascular Innovations Co Ltd, Nonthaburi, Thailand; a subsidiary of Sahajanand Medical Technologies Limited, India) in patients with symptomatic severe aortic stenosis at high or extremely high surgical risk.

Methods: The Hydra CE study was a prospective, multicenter, single-arm study.

View Article and Find Full Text PDF

Thrombogenic Risk Assessment of Transcatheter Prosthetic Heart Valves Using a Fluid-Structure Interaction Approach.

Comput Methods Programs Biomed

December 2024

Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794, USA. Electronic address:

Background And Objective: Prosthetic heart valve interventions such as TAVR have surged over the past decade, but the associated complication of long-term, life-threatening thrombotic events continues to undermine patient outcomes. Thus, improving thrombogenic risk analysis of TAVR devices is crucial. In vitro studies for thrombogenicity are typically difficult to perform.

View Article and Find Full Text PDF
Article Synopsis
  • Paravalvular leaks (PVL) after mitral valve replacement happen in 7% to 17% of cases, with 1% to 5% being serious.
  • Surgical repair is typically suggested, but transcatheter PVL closures have proven to have better results and fewer complications.
  • This case report explores a patient with a severe PVL following aortic and mitral valve replacement who was treated using a transapical approach, looking into the outcomes and possible complications.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!